Literature DB >> 3144537

The metabolism and pharmacokinetics of fleroxacin in healthy subjects.

D J Griggs1, R Wise, B Kirkpatrick, J P Ashby.   

Abstract

A 400 mg dose of fleroxacin was administered orally to six healthy male volunteers. Concentrations of fleroxacin and the N-demethyl and N-oxide metabolites were determined in serum and urine by HPLC. The serum metabolite levels were negligible. The N-oxide metabolite was measured in the serum of five subjects but did not exceed 4% of the corresponding fleroxacin level. N-demethyl fleroxacin was not detected (less than 0.1 mg/l). The urinary recovery of fleroxacin was 49.5% over 72 h; the N-demethyl and N-oxide metabolites accounted for 6.9% and 5.7%, respectively, of the administered dose.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3144537     DOI: 10.1093/jac/22.supplement_d.191

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  13 in total

1.  Fleroxacin pharmacokinetics in aqueous and vitreous humors determined by using complete concentration-time data from individual rabbits.

Authors:  M H Miller; A Madu; G Samathanam; D Rush; C N Madu; K Mathisson; M Mayers
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

2.  Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.

Authors:  E Singlas; A Leroy; E Sultan; M Godin; B Moulin; A M Taburet; M Dhib; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

Review 3.  Fleroxacin clinical pharmacokinetics.

Authors:  A E Stuck; D K Kim; F J Frey
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

4.  Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients.

Authors:  W L Hayton; V Vlahov; N Bacracheva; I Viachki; R Portmann; G Muirhead; K Stoeckel; E Weidekamm
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

5.  Fleroxacin pharmacokinetics in patients with liver cirrhosis.

Authors:  R A Blouin; B A Hamelin; D A Smith; T S Foster; W J John; H A Welker
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

6.  Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin.

Authors:  W R Bowie; V Willetts; P J Jewesson
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

7.  Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography.

Authors:  A J Fischman; E Livni; J W Babich; N M Alpert; A Bonab; S Chodosh; F McGovern; P Kamitsuka; Y Y Liu; R Cleeland; B L Prosser; J A Correia; R H Rubin
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

8.  Influence of rifampin on fleroxacin pharmacokinetics.

Authors:  J Schrenzel; P Dayer; T Leemann; E Weidekamm; R Portmann; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

9.  Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography.

Authors:  A J Fischman; E Livni; J Babich; N M Alpert; Y Y Liu; E Thom; R Cleeland; B L Prosser; J A Correia; H W Strauss
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

Review 10.  Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.

Authors:  J A Balfour; P A Todd; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.